BRAF and neoplasm: Furthermore, the combination of BRAF and MEK inhibitors (such as dabrafenib and trametinib, or vemurafenib and cobimetinib) improved tumour response rate and progression-free survival, while attenuating some of the serious adverse events observed with monotherapy [4, 5].